Nottingham Clinical Trials Unit
The University of Nottingham
University of Nottingham







Trial Name:  Systematic Evaluation of Aspirin and Fish Oil polyp prevention trial (seAfOod)

Chief Investigator:  Mark Hull, University of Leeds

Trial Description:  Colorectal cancer develops over a number of years from tumour initiation and benign adenoma (or polyp) growth, followed by transformation into malignant adenocarcinoma. Currently colorectal cancer prevention is aimed at detection and removal of asymptomatic colorectal polyps. Polyp removal does reduce bowel cancer risk, but does not prevent all cases of bowel cancer.

This factorial trial assessed the effects of eicosapentaenoic acid (fish oil) and/or aspirin for people with colorectal polyps attending for colonoscopic surveillance in the NHS Bowel Cancer Screening Programme. 709 participants were recruited into the trial. The trial completed in June 2017.  The primary outcome was recurrent polyp/s at surveillance colonoscopy.  The seAfOod Polyp Prevention Trial found no evidence of an effect of either eicosapentaeonic acid (fish oil) or aspirin on polyps at 12 month surveillance colonoscopy in patients deemed 'high risk' in the NHS Bowel Cancer Screening Programme.

Contact:  Aisha Shafayat 

Funding:  NIHR Efficacy and Mechanism Evaluation

Status: Published

Publications: 2013-6; 2015-48; 2018-19, 2019-12

Further Information:  Aisha Shafayat (Trial Manager)



Nottingham Clinical Trials Unit

General enquiries
Telephone: +44 (0)115 8231600